Logo image of CLDI

CALIDI BIOTHERAPEUTICS INC (CLDI) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:CLDI - US3207034089 - Common Stock

1.29 USD
-0.01 (-0.77%)
Last: 12/24/2025, 8:21:12 PM
1.29 USD
0 (0%)
After Hours: 12/24/2025, 8:21:12 PM
Fundamental Rating

1

Taking everything into account, CLDI scores 1 out of 10 in our fundamental rating. CLDI was compared to 530 industry peers in the Biotechnology industry. CLDI may be in some trouble as it scores bad on both profitability and health. CLDI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CLDI has reported negative net income.
CLDI had a negative operating cash flow in the past year.
In the past 5 years CLDI always reported negative net income.
In the past 5 years CLDI always reported negative operating cash flow.
CLDI Yearly Net Income VS EBIT VS OCF VS FCFCLDI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

CLDI has a Return On Assets of -212.30%. This is amonst the worse of the industry: CLDI underperforms 90.38% of its industry peers.
CLDI has a Return On Equity of -1125.40%. This is amonst the worse of the industry: CLDI underperforms 81.51% of its industry peers.
Industry RankSector Rank
ROA -212.3%
ROE -1125.4%
ROIC N/A
ROA(3y)-531.04%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLDI Yearly ROA, ROE, ROICCLDI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 2K 4K 6K 8K 10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CLDI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLDI Yearly Profit, Operating, Gross MarginsCLDI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -10K -20K -30K -40K -50K

More info and screens

2

2. Health

2.1 Basic Checks

CLDI has more shares outstanding than it did 1 year ago.
CLDI has a better debt/assets ratio than last year.
CLDI Yearly Shares OutstandingCLDI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 500K 1M 1.5M
CLDI Yearly Total Debt VS Total AssetsCLDI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M

2.2 Solvency

Based on the Altman-Z score of -26.05, we must say that CLDI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -26.05, CLDI is doing worse than 87.17% of the companies in the same industry.
CLDI has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.47, CLDI is doing worse than 72.08% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Altman-Z -26.05
ROIC/WACCN/A
WACCN/A
CLDI Yearly LT Debt VS Equity VS FCFCLDI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

2.3 Liquidity

A Current Ratio of 1.13 indicates that CLDI should not have too much problems paying its short term obligations.
CLDI has a worse Current ratio (1.13) than 86.98% of its industry peers.
A Quick Ratio of 1.13 indicates that CLDI should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.13, CLDI is doing worse than 86.04% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.13
Quick Ratio 1.13
CLDI Yearly Current Assets VS Current LiabilitesCLDI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 88.25% over the past year.
EPS 1Y (TTM)88.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 17.94% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y86.13%
EPS Next 2Y37.7%
EPS Next 3Y24.08%
EPS Next 5Y17.94%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLDI Yearly Revenue VS EstimatesCLDI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2029 2030 2031 20M 40M 60M
CLDI Yearly EPS VS EstimatesCLDI Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CLDI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLDI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLDI Price Earnings VS Forward Price EarningsCLDI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLDI Per share dataCLDI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

CLDI's earnings are expected to grow with 24.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.7%
EPS Next 3Y24.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLDI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CALIDI BIOTHERAPEUTICS INC

NYSEARCA:CLDI (12/24/2025, 8:21:12 PM)

After market: 1.29 0 (0%)

1.29

-0.01 (-0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/dmh
Earnings (Next)N/A N/A
Inst Owners3.32%
Inst Owner Change-92.35%
Ins Owners4.22%
Ins Owner Change6.97%
Market Cap9.25M
Revenue(TTM)N/A
Net Income(TTM)-19.85M
Analysts85.71
Price TargetN/A
Short Float %1.65%
Short Ratio0.6
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.49%
Min EPS beat(2)-19.24%
Max EPS beat(2)0.26%
EPS beat(4)2
Avg EPS beat(4)-7.07%
Min EPS beat(4)-34.77%
Max EPS beat(4)25.47%
EPS beat(8)5
Avg EPS beat(8)-13.23%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.24
P/tB 5.24
EV/EBITDA N/A
EPS(TTM)-12.48
EYN/A
EPS(NY)-5.68
Fwd EYN/A
FCF(TTM)-3.13
FCFYN/A
OCF(TTM)-3.12
OCFYN/A
SpS0
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -212.3%
ROE -1125.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-531.04%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.49%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.13
Quick Ratio 1.13
Altman-Z -26.05
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)148.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.67%
EPS Next Y86.13%
EPS Next 2Y37.7%
EPS Next 3Y24.08%
EPS Next 5Y17.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-102.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-104.2%
OCF growth 3YN/A
OCF growth 5YN/A

CALIDI BIOTHERAPEUTICS INC / CLDI FAQ

What is the ChartMill fundamental rating of CALIDI BIOTHERAPEUTICS INC (CLDI) stock?

ChartMill assigns a fundamental rating of 1 / 10 to CLDI.


Can you provide the valuation status for CALIDI BIOTHERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to CALIDI BIOTHERAPEUTICS INC (CLDI). This can be considered as Overvalued.


How profitable is CALIDI BIOTHERAPEUTICS INC (CLDI) stock?

CALIDI BIOTHERAPEUTICS INC (CLDI) has a profitability rating of 0 / 10.


How financially healthy is CALIDI BIOTHERAPEUTICS INC?

The financial health rating of CALIDI BIOTHERAPEUTICS INC (CLDI) is 2 / 10.